Home Tags Biotech
Healthcare deals hit an all-time record in 2018. See the 7 biggest tie-ups that could change how we buy drugs and treat diseases.
A record $421 billion in healthcare deals have been announced this year. A global pharma deal and a US insurance merger are among the largest.
Moderna Therapeutics started trading Friday in its initial public offering under the ticker "MRNA." The biotech raised more than $600 million.
The biotech Moderna is developing medical treatments based on messenger RNA, though it doesn't have any on the market yet.
The pharma giant GlaxoSmithKline just acquired the cancer-drug maker Tesaro for $5.1 billion in a bid to bulk up its cancer pipeline.
We asked some of the top young healthcare entrepreneurs in America for their advice — here’s what they said
Business Insider asked a few Forbes 30 under 30 healthcare superstars for their best career advice. Here's what they told us.
A pill to treat peanut allergies is getting closer to reality — but a new study shows the drug can have some harsh side effects
A new treatment for peanut allergies is moving closer to approval, but it's far from a cure. Taking the medicine can lead to some of the same allergic reactions.
A medical diagnostics startup that wants to use CRISPR technology to detect diseases raised $23 million in venture funding
Mammoth Biosciences, a diagnostics startup that uses CRISPR proteins to detect diseases like HPV and malaria, raised $23 million in funding to develop its technology.
The startup behind the first lab-grown pork links let us see how their sausage gets made — and said it slashed the cost from $2,500 to $216 in a...
New Age Meats, a Silicon Valley company funded by biotech startup hub IndieBio, let us taste the world's first cell-based pork sausage made without killing any animals in September. Since then, they've slashed production costs by 12x.
Pacific Biosciences jumped in late trading after Illumina offered to acquire the company in a $1.2 billion deal.
Its been a volatile year for the biotech sector, thanks to changing investor sentiment. In a new report, Goldman Sachs analysts told investors which biotech stocks they should own.